{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:28:40Z","timestamp":1782174520058,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"DOI":"10.7759\/cureus.48503","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T15:28:30Z","timestamp":1699457310000},"source":"Crossref","is-referenced-by-count":5,"title":["Carney Complex and Its Association With Thyroid Cancer, Molecular Pathway, and Treatment"],"prefix":"10.7759","author":[{"given":"Chetna","family":"Sachdev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh  G","family":"Gattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000345669","article-title":"Carney complex","volume":"41","author":"Espiard S","year":"2013","unstructured":"Espiard S, Bertherat J. Carney complex. Front Horm Res. 2013, 41:50-62. 10.1159\/000345669","journal-title":"Front Horm Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04328.x","article-title":"The essential role of RI alpha in the maintenance of regulated PKA activity","volume":"968","author":"Amieux PS","year":"2002","unstructured":"Amieux PS, McKnight GS. The essential role of RI alpha in the maintenance of regulated PKA activity. Ann N Y Acad Sci. 2002, 968:75-95. 10.1111\/j.1749-6632.2002.tb04328.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/79238","article-title":"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex","volume":"26","author":"Kirschner LS","year":"2000","unstructured":"Kirschner LS, Carney JA, Pack SD, et al.. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000, 26:89-92. 10.1038\/79238","journal-title":"Nat Genet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118467","article-title":"Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2","volume":"97","author":"Stratakis CA","year":"1996","unstructured":"Stratakis CA, Carney JA, Lin JP, et al.. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996, 97:699-705. 10.1172\/JCI118467","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3101","article-title":"Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice","volume":"99","author":"Pringle DR","year":"2014","unstructured":"Pringle DR, Vasko VV, Yu L, et al.. Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. J Clin Endocrinol Metab. 2014, 99:E804-12. 10.1210\/jc.2013-3101","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.115","article-title":"PAX8-PPAR\u03b3 fusion protein in thyroid carcinoma","volume":"10","author":"Raman P","year":"2014","unstructured":"Raman P, Koenig RJ. PAX8-PPAR\u03b3 fusion protein in thyroid carcinoma. Nat Rev Endocrinol. 2014, 10:616-23. 10.1038\/nrendo.2014.115","journal-title":"Nat Rev Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6340","article-title":"Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein","volume":"6","author":"Zhang Y","year":"2015","unstructured":"Zhang Y, Yu J, Lee C, Xu B, Sartor MA, Koenig RJ. Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein. Oncotarget. 2015, 6:40418-32. 10.18632\/oncotarget.6340","journal-title":"Oncotarget"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.308","article-title":"Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females","volume":"29","author":"Antico-Arciuch VG","year":"2010","unstructured":"Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A. Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene. 2010, 29:5678-86. 10.1038\/onc.2010.308","journal-title":"Oncogene"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.7.4079","article-title":"Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex)","volume":"82","author":"Stratakis CA","year":"1997","unstructured":"Stratakis CA, Courcoutsakis NA, Abati A, Filie A, Doppman JL, Carney JA, Shawker T. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab. 1997, 82:2037-43. 10.1210\/jcem.82.7.4079","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2333","article-title":"Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes","volume":"94","author":"Bertherat J","year":"2009","unstructured":"Bertherat J, Horvath A, Groussin L, et al.. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab. 2009, 94:2085-91. 10.1210\/jc.2008-2333","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0365","article-title":"Frequency of germline PTEN mutations in differentiated thyroid cancer","volume":"21","author":"Nagy R","year":"2011","unstructured":"Nagy R, Ganapathi S, Comeras I, et al.. Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid. 2011, 21:505-10. 10.1089\/thy.2010.0365","journal-title":"Thyroid"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000975","article-title":"The spectrum of thyroid gland pathology in Carney complex: the importance of follicular carcinoma","volume":"42","author":"Carney JA","year":"2018","unstructured":"Carney JA, Lyssikatos C, Seethala RR, Lakatos P, Perez-Atayde A, Lahner H, Stratakis CA. The spectrum of thyroid gland pathology in Carney complex: the importance of follicular carcinoma. Am J Surg Pathol. 2018, 42:587-94. 10.1097\/PAS.0000000000000975","journal-title":"Am J Surg Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0067","article-title":"Familial non-medullary thyroid cancer: unraveling the genetic maze","volume":"23","author":"Peiling Yang S","year":"2016","unstructured":"Peiling Yang S, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocr Relat Cancer. 2016, 23:R577-95. 10.1530\/ERC-16-0067","journal-title":"Endocr Relat Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/genes10070482","article-title":"Current knowledge of germline genetic risk factors for the development of non-medullary thyroid cancer","volume":"10","author":"Hi\u0144cza K","year":"2019","unstructured":"Hi\u0144cza K, Kowalik A, Kowalska A. Current knowledge of germline genetic risk factors for the development of non-medullary thyroid cancer. Genes (Basel). 2019, 10:482. 10.3390\/genes10070482","journal-title":"Genes (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.20.03338-6","article-title":"Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors","volume":"46","author":"Cirello V","year":"2021","unstructured":"Cirello V. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors. Minerva Endocrinol. 2021, 46:5-20. 10.23736\/S2724-6507.20.03338-6","journal-title":"Minerva Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/a-0753-4943","article-title":"Carney complex","volume":"127","author":"Kamilaris CD","year":"2019","unstructured":"Kamilaris CD, Faucz FR, Voutetakis A, Stratakis CA. Carney complex. Exp Clin Endocrinol Diabetes. 2019, 127:156-64. 10.1055\/a-0753-4943","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.40.4.268","article-title":"Chromosome 2 (2p16) abnormalities in Carney complex tumours","volume":"40","author":"Matyakhina L","year":"2003","unstructured":"Matyakhina L, Pack S, Kirschner LS, et al.. Chromosome 2 (2p16) abnormalities in Carney complex tumours. J Med Genet. 2003, 40:268-77. 10.1136\/jmg.40.4.268","journal-title":"J Med Genet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3432","article-title":"Assembly of allosteric macromolecular switches: lessons from PKA","volume":"13","author":"Taylor SS","year":"2012","unstructured":"Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PKA. Nat Rev Mol Cell Biol. 2012, 13:646-58. 10.1038\/nrm3432","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3620","article-title":"Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors","volume":"64","author":"Griffin KJ","year":"2004","unstructured":"Griffin KJ, Kirschner LS, Matyakhina L, et al.. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. Cancer Res. 2004, 64:8811-5. 10.1158\/0008-5472.CAN-04-3620","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00294-002-0308-9","article-title":"Molecular mechanisms controlling the localisation of protein kinase A","volume":"41","author":"Griffioen G","year":"2002","unstructured":"Griffioen G, Thevelein JM. Molecular mechanisms controlling the localisation of protein kinase A. Curr Genet. 2002, 41:199-207. 10.1007\/s00294-002-0308-9","journal-title":"Curr Genet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2215","article-title":"Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage","volume":"93","author":"Haymart MR","year":"2007","unstructured":"Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2007, 93:809-14. 10.1210\/jc.2007-2215","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0306","article-title":"Thyroid specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer","volume":"19","author":"Pringle DR","year":"2012","unstructured":"Pringle DR, Yin Z, Lee AA, et al.. Thyroid specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer. Endocr Relat Cancer. 2012, 19:435-46. 10.1530\/ERC-11-0306","journal-title":"Endocr Relat Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00769","article-title":"PKA activates AMPK through LKB1 signaling in follicular thyroid cancer","volume":"10","author":"Kari S","year":"2019","unstructured":"Kari S, Vasko VV, Priya S, Kirschner LS. PKA activates AMPK through LKB1 signaling in follicular thyroid cancer. Front Endocrinol (Lausanne). 2019, 10:769. 10.3389\/fendo.2019.00769","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1097\/00000478-199003000-00002","article-title":"Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome","volume":"14","author":"Carney JA","year":"1990","unstructured":"Carney JA. Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome.  Am J Surg Pathol. 1990, 14:206-22.","journal-title":"Am J Surg Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s1096-7192(03)00006-4","article-title":"Clinical and molecular genetics of Carney complex","volume":"78","author":"Sandrini F","year":"2003","unstructured":"Sandrini F, Stratakis C. Clinical and molecular genetics of Carney complex. Mol Genet Metab. 2003, 78:83-92. 10.1016\/s1096-7192(03)00006-4","journal-title":"Mol Genet Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0209","article-title":"Carney Complex: an update","volume":"173","author":"Correa R","year":"2015","unstructured":"Correa R, Salpea P, Stratakis C. Carney Complex: an update. Eur J Endocrinol Eur Fed Endocr Soc. 2015, 173:85-97. 10.1530\/EJE-15-0209","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2009.06.021","article-title":"Sporadic and familial medullary thyroid carcinoma, state of the art","volume":"89","author":"Moo-Young TA","year":"2009","unstructured":"Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma, state of the art. Surg Clin North Am. 2009, 89:1193-204. 10.1016\/j.suc.2009.06.021","journal-title":"Surg Clin North Am"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.08.001","article-title":"Tyrosine kinase inhibitors and the thyroid","volume":"23","author":"Sherman SI","year":"2009","unstructured":"Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009, 23:713-22. 10.1016\/j.beem.2009.08.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers G","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008, 8:592-603. 10.1038\/nrc2442","journal-title":"Nat Rev Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells SA","year":"2012","unstructured":"Wells SA, Robinson BG, Gagel RF, et al.. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012, 30:134-41. 10.1200\/JCO.2011.35.5040","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Brose MS","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, et al.. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014, 384:319-28. 10.1016\/S0140-6736(14)60421-9","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas ME","year":"2015","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, et al.. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015, 121:2749-56. 10.1002\/cncr.29395","journal-title":"Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1120","article-title":"Management of endocrine disease Carney complex: clinical and genetic update 20 years after the identification of the CNC1 (PRKAR1A) gene","volume":"184","author":"Bouys L","year":"2021","unstructured":"Bouys L, Bertherat J. Management of endocrine disease Carney complex: clinical and genetic update 20 years after the identification of the CNC1 (PRKAR1A) gene. Eur J Endocrinol. 2021, 184:99-109. 10.1530\/EJE-20-1120","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/198500-carney-complex-and-its-association-with-thyroid-cancer-molecular-pathway-and-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:18Z","timestamp":1707509418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/198500-carney-complex-and-its-association-with-thyroid-cancer-molecular-pathway-and-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.48503","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,8]]}}}